Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction
Autore:
Antman, EM; de Lemos, JA; Braunwald, E;
Indirizzi:
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA HarvardUniv Boston MA USA 02115 mens Hosp, Sch Med, Boston, MA 02115 USA
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: A, volume: 3, anno: 2001,
pagine: A8 - A13
SICI:
1520-765X(200105)3:A<A8:EFAMRF>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLASMINOGEN-ACTIVATOR; CORONARY THROMBOLYSIS; PERFUSION PATTERNS; RETEPLASE; TRIAL; ALTEPLASE; RESISTANCE; RESOLUTION; EXTENT; LYSIS;
Keywords:
abciximab; GP IIb/IIIa receptor; TIMI 14; perfusion; microvascular; ST-segment resolution;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Braunwald, E Harvard Univ, Brigham & Womens Hosp, Sch Med, 75 Francis St, Boston, MA 02115 USA Harvard Univ 75 Francis St Boston MA USA 02115 , MA 02115 USA
Citazione:
E.M. Antman et al., "Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction", EUR H J SUP, 3(A), 2001, pp. A8-A13

Abstract

Recent evidence from the Thrombolysis in Myocardial Infarction (TIMI) 14 trial suggests that combining reduced-dose fibrinolytic therapy with the potent platelet inhibition afforded by a glycoprotein (GP) IIb/IIIa receptor antagonist can help overcome the limitations of fibrinolytic therapy alone. The TIMI 14 investigators found that low-dose alteplase in combination withabciximab significantly increased the incidence of TIMI 3 flow at 60 and 90 min compared with full-dose alteplase. The use of abciximab emerged as one of the three principal determinants of TIMI 3 flow, along with time to treatment and location of the occlusive thrombus. Complete ST-segment resolution, reflecting perfusion at the myocardial tissue level, was a significantpredictor of 30-day survival in the TIMI 14 study. Patients treated with abciximab plus reduced-dose fibrinolytic therapy had significantly greater median ST-segment resolution and a significantly higher rate of complete ST-segment resolution than patients given fibrinolytic therapy alone. Similar benefits were observed in TIMI 14 patients who underwent early adjunctive percutaneous coronary intervention following combined therapy with abciximaband reduced-dose fibrinolysis. These findings indicate that a strategy coupling abciximab with reduced-dose fibrinolytic therapy not only enhances epicardial flow but also improves myocardial reperfusion following acute myocardial infarction.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 19:55:09